lrrk2 (wt)

CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.

LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.

CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM 6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.

JH-II-127 is an oral inhibitor of leucine-rich repeat kinase 2 (LRRK2), targeting WT LRRK2, G2019S LRRK2, and A2016T LRRK2 with IC50 values of 6.6 nM, 2.2 nM, and 47.7 nM, respectively.

PF-06454589 is a potent inhibitor of LRRK2.

LRRK2-IN-6 (compound 22) is an orally active, selective leucine-rich repeat protein kinase 2 (LRRK2) inhibitor with blood-brain barrier permeability, inhibiting GS LRRK2 (IC50: 4.6 μM) and WT LRRK2 (IC50: 49 μM). LRRK2-IN-6 exhibited inhibitory effects on the autophosphorylation of LRRK2 at Ser1292 and Ser925.

XL01126, a potent degrader of LRRK2, exhibits DC50 values of 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2), respectively. It has the ability to cross the blood-brain barrier, making it a viable degrader probe for Parkinson's disease research. This compound is instrumental in exploring the non-catalytic and scaffolding functions of LRRK2 [1].

GSK2578215A is a potent and selective LRRK2 kinase inhibitor.

Lu AF58786 is a novel potent and selective inhibitor of LRRK2, inhibiting LRRK2 WT, the overactive variant G2019S, and the resistant mutant A2016T56 at 12 nM, 19 nM and 93 nM, respectively.

PF-06447475 trihydrochloride is a potent, selective LRRK2 kinase inhibitor that demonstrates excellent brain penetration, exhibiting IC50 values of 3 nM for wild-type LRRK2 and 11 nM for G2019S LRRK2 variants. It holds potential for Parkinson's disease (PD) research [1].

LRRK2-IN-5 (compound 25) is an orally active, blood-brain barrier-penetrating, selective leucine-rich repeat protein kinase 2 (LRRK2) inhibitor, effective for GS LRRK2 (IC50: 1.2 μM) and WT LRRK2 (IC50: 16 μM), and can inhibit the autophosphorylation of LRRK2 at Ser1292 and Ser925.

LRRK2 NUAK1 TYK2-IN-1 (compound 226) exhibits inhibitory activity against LRRK2 (Wt), LRRK2 (G2019), TYK2, and NUAK1, demonstrating IC50 values below 10 nM. This compound is useful for research into autoimmune diseases.

LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].